Pharmacy Benefit Managers (PBMs) were established in the 1960s to control drug costs but have since morphed into one of the most highly concentrated...
A Stigler Center webinar explores how businesses lobby and compete for political power and whether mergers and industry concentration affect lobbying.
Firms compete in markets,...
The Clinton DOJ attacked international cartels. The Obama DOJ prioritized merger enforcement. The Biden DOJ needs to focus on America’s monopoly problem.
Antitrust is like...
In an interview with ProMarket, antitrust scholar, lawyer, and businesswoman Dina Srinivasan explains why she believes that if users were given the choice to...
Do the new iOS 14 privacy features violate antitrust laws? If Facebook brings an antitrust suit against Apple, as it is reportedly considering, there...
A Stigler Center webinar explores instances where competition turns toxic, whether antitrust policy needs reform, and potential paths forward.
Is there such a thing as...
Targeted at Big Tech, Germany’s new antitrust tool for dealing with large digital platforms rebalances the power between the competition watchdog and those firms.
Around...
Due to lack of transparency and mystery rebates, which are considered trade secrets, figuring out the price of a prescription drug is devilishly difficult....
How the pre-merger notification regime came about and why we should be careful about discouraging useful mergers.
December 2020 was an extraordinary period in US...